Evidence map›Paper›PMID 39359266›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Stimulation of fracture mineralization by salt-inducible kinase inhibitors.

Kaveh Momenzadeh, Diana Yeritsyan, Mohammadreza Abbasian, Nadim Kheir, Philip Hanna, Jialiang Wang, Pere Dosta, Garyfallia Papaioannou, Sarah Goldfarb, Cheng-Chia Tang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kaveh Momenzadeh *Musculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Diana Yeritsyan *Musculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Mohammadreza AbbasianMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Nadim KheirMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Philip HannaMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Jialiang WangThe Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Pere DostaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Garyfallia PapaioannouEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Sarah GoldfarbEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Cheng-Chia TangEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Eliz Amar-LewisBrigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Michaela Nicole Prado LarreaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Edith Martinez LozanoMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Mohamed YousefMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
John WixtedMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Marc WeinEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Natalie ArtziBrigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Ara NazarianMusculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Over 6.8 million fractures occur annually in the US, with 10% experiencing delayed- or non-union. Anabolic therapeutics like PTH analogs stimulate fracture repair, and small molecule salt inducible kinase (SIK) inhibitors mimic PTH action. This study tests whether the SIK inhibitor YKL-05-099 accelerates fracture callus osteogenesis. Methods: 126 female mice underwent femoral shaft pinning and midshaft fracture, receiving daily injections of PBS, YKL-05-099, or PTH. Callus tissues were analyzed via RT-qPCR, histology, single-cell RNA-seq, and μCT imaging. Biomechanical testing evaluated tissue rigidity. A hydrogel-based delivery system for PTH and siRNAs targeting SIK2/SIK3 was developed and tested. Results: YKL-05-099 and PTH-treated mice showed higher mineralized callus volume fraction and improved structural rigidity. RNA-seq indicated YKL-05-099 increased osteoblast subsets and reduced chondrocyte precursors. Hydrogel-released siRNAs maintained target knockdown, accelerating callus mineralization. Discussion: YKL-05-099 enhances fracture repair, supporting selective SIK inhibitors' development for clinical use. Hydrogel-based siRNA delivery offers targeted localized treatment at fracture sites.

Indexed as

bonefracture repairmicroparticlenanoscale drug deliveryPTHSIK2/SIK3 inhibitorsiRNA targeting

Identifiers

PMID39359266
PMCPMC11445660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.